ANTX
AN2 Therapeutics Inc
4.90$
-0.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | +2,335.0% | +350.8% | +91.6% | -0.9% | -25.1% | |
| – | -63.0% | -85.4% | +267.7% | – | – | – | |
| – | – | -97.4% | +11,518.8% | +56.9% | -151.3% | – | |
| – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | -56.5% | +98.8% | – | -48.1% | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | |
| – | -52.5% | +1,947.3% | -10.4% | +20.8% | -99.6% | -69.6% | |
| – | -127.3% | – | +88.4% | -176.5% | – | -124.7% | |
| – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.